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The inhibitory mechanism of Hal3 
on the yeast Ppz1 phosphatase:  
A mutagenesis analysis
Cristina Molero1, Carlos Casado1,2 & Joaquín Ariño1
The Ser/Thr protein phosphatase (PPase) Ppz1 is an enzyme related to the ubiquitous type-1 PPases 
(PP1c) but found only in fungi. It is regulated by an inhibitory subunit, Hal3, which binds to its catalytic 
domain. Overexpression of Ppz1 is highly toxic for yeast cells, so its de-regulation has been proposed 
as a target for novel antifungal therapies. While modulation of PP1c by its many regulatory subunits 
has been extensively characterized, the manner by which Hal3 controls Ppz1 remains unknown. 
We have used error-prone PCR mutagenesis to construct a library of Ppz1 variants and developed a 
functional assay to identify mutations affecting the binding or/and the inhibitory capacity of Hal3. We 
have characterized diverse Ppz1 mutated versions in vivo and in vitro and found that, although they 
were clearly refractory to Hal3 inhibition, none of them exhibited significant reduction in Hal3 binding. 
Mapping the mutations strengthened the notion that Hal3 does not interact with Ppz1 through its 
RVxF-like motif (found in most PP1c regulators). In contrast, the most relevant mutations mapped to 
a conserved α-helix region used by mammalian Inhibitor-2 to regulate PP1c. Therefore, modulation of 
PP1c and Ppz1 by their subunits likely differs, but could share some structural features.
Protein phosphorylation is a widespread mechanism for controlling cellular processes. The phosphorylation state 
of a given protein results from the opposing activities of protein kinases and protein phosphatases (PPases). Yeast 
cells contain different kinds of PPases that are also found in other eukaryotic organisms, including humans, while 
they also contain fungal-specific enzymes, such as the Ppz1 Ser/Thr protein phosphatase. Ppz1 is composed of 
a catalytic carboxyl-terminal domain, which is approximately 60% identical to the ubiquitous catalytic subunit 
of protein phosphatase 1 (PP1c), and a largely unstructured NH2-terminal extension1. In budding yeast, Ppz1 is 
involved in the regulation of monovalent ion homeostasis, by inhibiting the expression of the Na+/K+-ATPase 
Ena12, 3 and the transport of potassium through the Trk1/Trk2 high-affinity transporters4, 5. Consequently, ppz1 
deletion mutants are tolerant to toxic Na+ and Li+ cations2. These regulatory effects impact on diverse cellular 
functions, such as cell wall integrity and osmotic stability4, 6, 7, translational efficiency8, and progress through the 
cell cycle9. It is worth noting that recent work has identified Ppz1 as one of the most toxic proteins when overex-
pressed in budding yeast10, although the molecular basis for this effect is unknown.
Ppz1 is regulated in vivo by Hal3/Sis2, a protein originally identified as a high-copy suppressor of the sit4 cell 
cycle-related growth defect11 and by its capacity to confer halotolerance12. Hal3 binds to the carboxyl-terminal 
catalytic domain of Ppz1 and strongly inhibits its phosphatase activity, thus modulating its diverse physiological 
functions13. For that reason, cells overexpressing Hal3 are salt-tolerant, whereas a hal3 strain is hypersensitive 
to sodium and lithium cations. Similarly, high-copy expression of Hal3 exacerbates the lytic phenotype of a Slt2 
MAP kinase mutant, whereas, in contrast, lack of HAL3 improves growth of this strain13. The S. cerevisiae genome 
contains a paralog of Hal3, named Vhs3, which also inhibits Ppz1 in vitro, although its role regulating the phos-
phatase in vivo is far less important, probably due to lower expression levels14. The ability of Hal3-related proteins 
to bind to and inhibit Ppz1 phosphatases has been demonstrated in the past for several, phylogenetically distant 
fungal species, suggesting that this is a conserved mechanism15–18.
This relatively simple scenario is complicated by the fact that Hal3 (and Vhs3) are moonlighting proteins 
that, in addition to regulating Ppz1, are components of an unusual heterotrimeric PPC decarboxylase (PPCDC) 
enzyme that is crucial for Coenzyme A biosynthesis in S. cerevisiae and other related fungi16, 17, 19–21. The func-
tional heterotrimer requires Cab3, a Hal3-related protein that provides a catalytic Cys residue absent in Hal3 or 
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Vhs3. Earlier work identified a number of residues in the conserved domain of S. cerevisiae Hal3 that are neces-
sary for binding and/or inhibition of Ppz1, and revealed that these residues were unrelated to those required for 
PPCDC enzymatic function22.
The fact that Ppz1 is found only in fungi, including pathogenic ones, such as Candida albicans15, 23 or 
Aspergillus fumigatus24 and that increased Ppz1 function has a detrimental effect on yeast growth9, 10, 13 sug-
gest that this enzyme may represent an interesting target for the development of antifungal therapies. However, 
because of the relative similarity between the catalytic domain of Ppz1 and that of the ubiquitous type 1 enzymes, 
it might be argued that specificity could be an important issue when interfering with Ppz1 function in vivo. In fact, 
when this work was started, there was evidence suggesting that diverse regulatory subunits of Glc7, the essential 
budding yeast type-1 phosphatase25, 26 could bind to Ppz1, and that at least one of them, Glc8, might regulate 
Ppz1-related functions at least partially27. However, other evidence pointed towards the possibility of significant 
regulatory differences between PP1c and Ppz1 enzymes. For instance, Ppz1 was shown to be less sensitive than 
rabbit PP1c to mammalian inhibitor-228. In addition, the Glc7 regulatory subunit Ypi1 effectively binds to Ppz1, 
but barely inhibits its phosphatase activity in vitro nor it is able to mimic Ppz1-related Hal3 functions in vivo29.
Interestingly, Hal3 does not appear structurally similar to known PP1c phosphatase inhibitors, with the excep-
tion of a KLHVLF sequence starting at residue 263, which resemble a relatively conserved sequence found in 
many PP1c regulatory subunits, known as the RVxF motif30. However, Hal3 does not bind to or inhibit the yeast 
PP1c in vitro13, 29, indicating a strong specificity towards Ppz1. Moreover, mutation of the RVxF-like motif did 
not alter the in vivo or in vitro properties of Hal322, suggesting that the mechanism by which Hal3 interacts and 
inhibits Ppz1 might differ from those found for the regulatory subunits of mammalian PP1c. On the basis of this 
evidence, we decided to study the mechanisms that allow the specific inhibition of Ppz1 by Hal3. To this end, we 
created a library of C-terminally targeted mutated versions of Ppz1 and developed a functional in vivo screen to 
search for deregulated enzymes. The results of this screen, presented here, confirm the notion that Hal3 inhibits 
Ppz1 in a way that differs from known regulators of mammalian PP1c enzymes, although it might retain some 
common structural features.
Results
Screen of a random-mutagenesis library for deregulated versions of Ppz1. The rationale of the 
screen was based on the previous observation that the absence of Hal3, the Ppz1 negative regulator, improves tol-
erance to caffeine in a cell-wall sensitive strain which lacks the Slt2 MAP kinase. Therefore, we hypothesized that 
a strain expressing a version of Ppz1 unable to bind to Hal3, or to be inhibited by it, could mimic the behaviour of 
the hal3 mutation in a slt2 background. Both centromeric and 2-micron vectors were tested, and finally the library 
was generated in the pRS316 centromeric plasmid to avoid the negative growth effect caused by high-copy num-
ber expression of Ppz113. This library, carrying copies of Ppz1 randomly mutagenized between amino acids 351 
and 59 nt downstream the stop codon, was transformed into strain JC010 (slt2Δ) and plated on synthetic medium 
including 4 mM caffeine. Under these conditions, slt2 cells carrying a normal copy of Ppz1 cannot grow. Clones 
yielding macroscopic colonies after 3 days were selected, and their caffeine-tolerant phenotype was assessed by 
drop tests on plates containing 3, 4 or 5 mM caffeine. A total number of 36 clones were selected and the relevant 
Ppz1-encoding region sequenced. As shown in Supplementary File 1, several clones contained more than one 
change affecting the encoded amino acid. However, several clones included a single amino acid change and this 
subset was selected for further analysis (Table 1).
Phenotypic analysis of mutated alleles of PPZ1. The growth of selected clones carrying a single amino acid muta-
tion was examined on caffeine plates and compared with that of the slt2 strain transformed with the native PPZ1 
gene and the slt2 hal3 strain (which would mimic a largely derepressed Ppz1 activity). As shown in Fig. 1, clone 
97 (and its equivalent 141) and clone 124 (and its equivalent 139 and 143) exhibited a rather strong phenotype, 
with a tolerance to caffeine higher than that of native Ppz1 and similar to that of the slt2 hal3 strain. These clones 
harbor mutations of Glu to Gly at residues 630 and 575, respectively (Table 1). Clones 116 (Ile519 to Ser), 125 
(Lys502 to Gln), 132 (Thr513 to Ala), 136 (Glu389 to Lys), and 151 (Ser579 to Gly) also showed higher tolerance than 
cells carrying native Ppz1, although the phenotype was less apparent. The behaviour of the different clones was 
also tested in liquid cultures, as documented in Supplementary File 2, and the time required to reach OD600 = 0.2 
Clone Nt position Nt change AA change Ppz1 residue Notes
136 1165 GAA → AAA Glu → Lys 389
99 1282 TTA → GTA Leu → Val 428
125(a) 1504 AAG → CAG Lys → Gln 502
132 1538 ACA → GCA Thr → Ala 513
116 1556 ATC → AGC Ile → Ser 519
124 1724 GAA → GGA Glu → Gly 575 1
151 1735 AGT → GGT Ser → Gly 579
97(b) 1889 GAA → GGA Glu → Gly 630
149 2053 ACA → CCA Thr → Pro 685
Table 1. Mutations affecting the catalytic domain of Ppz1 that result in single amino acid change. (a)Same 
than clone 126. (b)Same than clone 141. (1) Mutation also found in clones 139 and 143 (these clones carry an 
additional mutation at nt 1296 that do not change amino acid).
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was calculated as described in Methods. These values confirmed that clones 97 and 124 exhibited the strongest 
phenotype (9.81 ± 0.09 and 10.44 ± 0.10 h, respectively) compared to cells carrying native Ppz1 (12.75 ± 0.09 h), 
and approaching that of slt2 hal3 cells (8.92 ± 0.05 h).
The activity of Ppz1 influences tolerance to toxic monovalent cations, such as Li+ and Na+. Thus, lack of Ppz1 
increases tolerance to Li+, whereas increased Ppz1 activity, such as found in hal3 mutants, decreases tolerance to 
this cation below the level of wild type cells. Thus, we tested the effect of expression of the diverse Ppz1 variants 
identified in our screen in cells exposed to high concentrations of Li+ cations. As shown in Fig. 2a, clones 97 and 
124 showed again the strongest phenotype, similar to that of the hal3 mutant. Clone 151 also displayed remarka-
ble sensitivity to this cation, whereas clones 125 and 132 were nearly as sensitive as the hal3 strain.
We then determined whether the different phenotypes observed could be the result of variations in the expres-
sion levels of the different Ppz1 variants. To this end, we prepared protein extracts from cultures of the different 
clones and carried out immunoblot analyses using a polyclonal antibody developed against recombinant Ppz11. 
As shown in Fig. 2b, all variants of Ppz1 were expressed at fairly equal levels. Integration of the signals indicated 
that the possible differences were not higher than 20% with respect the mean expression value and that there was 
Figure 1. Growth on caffeine plates of selected Ppz1 clones carrying single amino acid mutations. The indicated 
strains were transformed with pRS316-based plasmids (centromeric, URA3 marker) carrying the indicated 
versions of Ppz1. Cultures were spotted at OD660 = 0.05 and at 1/10 dilution, and plates were grown for 72 h.  
Ø, empty plasmid.
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no correlation between the relative abundance of a given variant and its phenotypic effects (for instance, clone 124 
showed the lowest expression value, but caused very strong phenotypes). In addition, the expression of the diverse 
variants did not differ from that of native Ppz1 expressed from its chromosomal locus. Therefore, the different 
cellular properties conferred by expression of the specific variants of Ppz1 are not likely to be due to variations in 
the amount of the phosphatase, but derived from the intrinsic properties of these variants. Interestingly, when the 
constructs 97 and 124 were introduced into a slt2 hal3 strain, we did not observe any different in the tolerance to 
caffeine conferred by these variants in comparison with that of the wild type phosphatase (Supplementary File 3). 
Similarly, mutation of HAL3 in the ppz1 background did not allow distinguishing wild type from mutated variants 
when tolerance to lithium ions was tested (Supplementary File 3). These results strongly support the notion that 
the impact caused in the cell by expression of these Ppz1 variants is caused by the inability of these versions to be 
inhibited by Hal3.
During the course of the phenotypic characterization, we noticed a tendency to aggregate when certain Ppz1 
variants were expressed in cells carrying the slt2 mutation. This was interesting, because previous evidence linked 
the appearance of a flocculent phenotype to the hyperactivation of Ppz114, 31. Therefore, we set up a quantitative 
flocculation test for the strains expressing the different Ppz1 versions. As shown in Supplementary File 4, expres-
sion of Ppz1 in the slt2 background has no effect on flocculation, whereas additional deletion of HAL3 increased 
the flocculation index by two-fold. Interestingly, slt2 cells expressing Ppz1 variants 97 and 124 displayed a signif-
icantly increased flocculation index, further confirming that these two mutations greatly affected Ppz1 function 
in vivo. Cells expressing variant 141 (equivalent to 97), as well as variants 139 and 143 (equivalent to 124) also 
displayed an enhanced tendency to flocculate (not shown).
Determination of the capacity Hal3 to inhibit the Ppz1 variants. As described above, the aim of our screen was 
to identify Ppz1 residues important for binding to or inhibition by the negative regulator Hal3. However, it could 
be also argued that a similar effect could be achieved if a given mutation would enhance the activity of the phos-
phatase in a way that normal cellular levels of Hal3 would be unable of properly down-regulate Ppz1 activity. 
To evaluate this possibility, we expressed the different Ppz1 variants in E. coli as GST fusions, affinity-purified 
the proteins and, upon removal of the GST tag, tested their phosphatase activity. As observed in Supplementary 
File 5, the mutations did not greatly alter the specific activity of Ppz1 and, with the exception of clones 116, 
124 and 151, the changes resulted in a phosphatase slightly less active than the native protein. These differences 
could be due, at least in part, to the difficulty to accurately determine the amount of purified recombinant Ppz1 
(see Methods and Supplementary File 5) and, consequently, they might not reflect actual relevant differences. 
Figure 2. Tolerance to Li+ cations conferred by the diverse variants of the Ppz1 phosphatase. (a) The indicated 
strains were transformed with the diverse versions of Ppz1, and cultures were spotted as in Fig. 1 and grown for 
72 h in the presence of various concentrations of LiCl. (b) Protein extracts (40 μg) from the indicated strains 
were subjected to electrophoresis on 10% polyacrylamide-SDS gels. Proteins were transferred to membranes 
and probed with a polyclonal anti-GST-Ppz1 antibody. Ø, empty plasmid; WT, wild type.
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Therefore, it is unlikely that the observed phenotypic effects are derived from the expression of intrinsically 
hyperactive forms of the phosphatase.
We then tested the ability of Hal3 to inhibit the different versions of Ppz1 by incubating stoichiometric amounts 
of the inhibitor with the phosphatase prior to initiating the assay. As shown in Fig. 3, the Ppz1 versions derived 
from clones 97 and 124 were clearly refractory to inhibition by Hal3. The behaviour of Ppz1 from clone 97 closely 
corresponded to that observed for the phosphatase variant derived from clone 141, which harbours the same 
amino acid change. Similarly, the inhibition profiles of clones 139 and 143 were equivalent to that of clone 124. 
This was in agreement with the observation that these clones displayed the strongest phenotypic effects (see Figs 1 
and 2). A similar behaviour was observed when these variants were incubated with Vhs3 (not shown), which 
inhibits Ppz1 in vitro with an efficiency similar to that of Hal314. Ppz1 proteins from clones 151, 136 and, to some 
extent, from clone 125 (and its equivalent 126, not shown), were less sensitive to Hal3 inhibition than the native 
phosphatase. It must be noted that the inability of Hal3 to completely inhibit wild type full length Ppz1 is not 
surprising, since it is known that the N-terminal half of the phosphatase hinders binding of the inhibitor13, 14, 16, 17.
Ppz1 variants retain the ability to bind Hal3. The observation that certain Ppz1 variants were not inhibited by 
Hal3 could be explained if the mutation in Ppz1 would abolish the ability of Hal3 to bind to the phosphatase. To 
test this possibility we used two different strategies. First, employed the recombinant versions of the GST-Ppz1 
variants and used them as an affinity system to recover HA-tagged Hal3 from a yeast protein extract. The results 
of this experiment, shown in Fig. 4a, indicate that all tested Ppz1 variants interacted with quite similar efficiency. 
Quantification of the Hal3/Ppz1 signal ratio from 3 independent experiments yielded values ranging from 
0.79 ± 0.09 (clone 116) to 1.22 ± 0.22 (clone 136), with a ratio for native Ppz1 of 1.14 ± 0.14. To confirm these 
findings we carried out a second approach based on the co-expression of a selection of the different His-tagged 
catalytic Ppz1 domains, together with Hal3, using a polycistronic vector. In this way, after affinity purification of 
Ppz1 using a Ni+-based resin, the untagged Hal3 is recovered only if it binds efficiently to Ppz1. The results of 
this approach are presented in Fig. 4b and confirm that Hal3 can be recovered in roughly the same amounts in all 
cases. Therefore, it can be assumed that the incapacity of Hal3 to inhibit Ppz1 versions such as 97 or 124 is related 
to the intrinsic inhibitory mechanism and not to substantial loss of binding to the phosphatase.
Characterization of additional PPZ1 alleles. As documented in Supplementary File 1, our screen revealed 
numerous alleles carrying more than one amino acid changes. Among those, we selected four of them for further 
analysis (Table 2). Clones 75 and 120 were selected because they showed a strong phenotype in the initial screen 
and shared a common modification, the exchange of Val605 to Ala (the mutations in clone 120 were also present in 
clones 85, 100 and 140, see Supplementary File 1). Clone 121 showed the change of Phe436 and Phe631 to Leu, and 
was selected because Phe631 is the residue following the single Glu630 to Gly change found in clone 97 (identical 
mutations were found in clones 138, 153 and 168). Similarly, clone 129 carries the mutations Glu365 to Gly and 
Asn574 to Ser, of which the change affecting position 574 precedes the single Glu to Gly mutation found in clone 
124. All four clones were evaluated for tolerance to caffeine in the slt2 background and to Li+ cations in the ppz1 
Figure 3. Ppz1 variants show differences in the pattern of in vitro inhibition by Hal3. p-nitrophenyl phosphate 
dephosphorylation assays were carried out as described under Methods. Six-hundred ng of the different 
affinity-purified Ppz1 variants were pre-incubated for 5 min with increasing amount of Hal3 prior starting the 
assay. Values are means ± S.E. for 4 to 12 different assays, and are expressed as the percentage of phosphatase 
activity relative to control without inhibitor. The dashed line at 50% activity is included to facilitate comparisons 
between panels.
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background. As deduced from Fig. 5a and b, all clones exhibited a rather strong phenotype compared with that 
of cells carrying the wild type phosphatase. Tolerance to caffeine was also confirmed by continuous monitoring 
of growth in liquid culture (Supplementary File 6). In addition, when variants 120 and 121 were introduced in 
the slt2 hal3 or in the ppz1 hal3 backgrounds, and the resulting strains tested, respectively, for caffeine and LiCl 
tolerance, these phenotypic differences were abolished (Supplementary File 3). All four variants also increased 
the ability of slt2 cells to flocculate (Supplementary File 4). These phenotypic effects were not due to differences in 
Figure 4. Interaction of Hal3 with the different Ppz1 variants. (a) Equal amounts of the indicated versions of 
GST-Ppz1 were immobilized on glutathione beads and used as an affinity system to recover plasmid-borne 
HA-tagged Hal3 from extracts of strain IM021 (ppz1 hal3). Beads were washed and processed for SDS-PAGE 
(8% gels) and immunoblotting using anti-HA antibodies as described in Methods. The lower panel corresponds 
to the Ponceau-stained membranes, to reveal the amount of Ppz1. (b) Co-expression and co-purification of 
Ppz1 variants and Hal3 in E. coli. Several 6xHis-tagged Ppz1-Cter versions carrying selected mutations were 
co-expressed together with untagged Hal3 in a polycistronic vector under the T7 promoter. The left panel shows 
bacterial extracts corresponding to the wild type Ppz1 as an example (−, non-induced; +, induced). The 6x-His 
tagged Ppz1-Cter proteins were purified by Ni-NTA agarose affinity chromatography and the protein complex 
subsequently eluted with buffer containing 500 mM imidazole. Samples (15 μl) were analyzed by 10% SDS-
PAGE and proteins revealed with BlueSafe protein stain.
Clone Nt position Nt change AA change Ppz1residue Notes
75(a)
1331 TTC → TCC Phe → Ser 444
1814 GTT → GCT Val → Ala 605 1
120(b)
1070 TTC → TCC Phe → Ser 357
1814 GTT → GCT Val → Ala 605
121(c)
1306 TTC → CTC Phe → Leu 436
1893 TTT → TTG Phe → Leu 631 2
129
1094 GAA → GGA Glu → Gly 365
1721 AAC → AGC Asn → Ser 574 3
Table 2. Mutations affecting the catalytic domain of Ppz1 that result in changes in two amino acids. (a)Identical 
to clone 144. (b)Identical to clones 85, 100 and 140. These clones include also changes at nucleotides 1806 (GCT 
to GCC) and 1845 (GAT to GAC) that do not modify the encoded amino acid. (c)Identical to clones 138, 153 and 
168. (1) Same mutation than clone 120 (also found in clones 85, 100, 140, and 144). (2) Follows single amino 
acid mutation in clone 97. (3) Precedes single amino acid mutation in clone 124.
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the amount of expressed Ppz1, as the protein levels of the different Ppz1 versions did not significantly differ from 
those of the native enzyme (Fig. 5b).
We then tested the ability of these Ppz1 variants to interact with Hal3. As shown in Fig. 6a, the different ver-
sions of Ppz1 expressed in E. coli as GST-fusion proteins and bound to glutathione-agarose beads were still able to 
bind Hal3 with similar efficiency. At this level we observed that expression in E. coli of clone 75 was clearly poorer 
than the wild type or the other variants. The ability of Hal3 to inhibit the Ppz1 versions carrying two amino acid 
Figure 5. Phenotypic analysis and expression levels of selected Ppz1 versions carrying two amino acid changes. 
(a) Yeast strains were transformed with the diverse versions of Ppz1 and cultures spotted in the presence of 
various concentrations of caffeine or LiCl, as in Figs 1 and 2. Pictures were taken after 72 h. (b) Protein extracts 
(40 μg) were analyzed as described in Fig. 2b. Ø, empty plasmid; WT, wild type.
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changes was evaluated by removing the GST tag with the PreScission protease from the Ppz1 variants. As shown 
in Fig. 6b, Hal3 was completely unable to inhibit the Ppz1 corresponding to clone 120, whereas clone 121 was 
clearly refractory to inhibition compared with native Ppz1. The lack of inhibition observed for these versions fits 
well with the intensity of the phenotypes determined in vivo. In contrast, Hal3-mediated inhibition of the Ppz1 
variant from clone 129 was only slightly less effective than that of native Ppz1. This was somewhat surprising, 
since the phenotypes observed upon expression of this clone in yeast were similar to those of clone 121. We were 
unable to perform inhibition experiments with the Ppz1 version from clone 75 since all attempts to release the 
phosphatase from the affinity matrix in a soluble and active form failed. Identical results were obtained using 
clone 144, which harbours the same two mutations. Clones 75 and 120 share a common mutation (Val605 to Ala), 
but differ in the second mutation. Since clone 120 was successfully expressed and showed full activity, we assume 
that the second mutation in clone 75 (Phe444 to Ser) could be responsible for the instability of the resulting protein 
when expressed in bacteria.
Mapping the mutations in Ppz1 and PP1c sequences. The sequences corresponding to the C-terminal halves of S. 
cerevisiae and C. albicans were aligned with that of the entire S. cerevisiae (Glc7) and human PP1 catalytic (PP1c) 
subunits and the different mutations characterized in this work were highlighted in the ScPpz1 sequence (Fig. 7). 
Based on the work of Chen and coworkers32, we selected those residues that define the regulatory motifs in mam-
malian PP1c that are highly conserved in the fungal Ppz1 proteins, such as those required for interaction with the 
RVxF, Inhibitor-2 helix, Arg, NIPP1-helix, or SILK motifs present in regulatory subunits of PP1c, and annotated 
them in the alignment. Comparison of the selected residues with the mutations found in this work clearly shows 
that, as a rule, none of the mutations are within these regulatory binding motifs, in particular with the highly con-
served RVxF-binding motif present in most PP1c regulatory subunits. Notably, the only exception were Glu575, 
Val605, Glu630, and Phe631, which corresponded to PP1c residues (Glu575 being an Asp residue in PP1c) known to 
interact with the Inhibitor-2 helix33. It must be noted that these are the Ppz1 mutations that cause the strongest 
phenotypes. To obtain a deeper insight into the relative position of these mutations in the S. cerevisiae Ppz1 pro-
tein we created a three-dimensional model of the budding yeast phosphatase C-terminal domain, taking advan-
tage of the recently solved 3D structure of the catalytic domain of its C. albicans homolog. As shown in Fig. 8, 
virtually all of the functionally relevant mutations found in this work are located at the surface and on the same 
side of the phosphatase, which corresponds to the access to the catalytic site. This clustering of mutations fits well 
with a role for these residues being relevant in the modulation of the phosphatase activity by the Hal3 inhibitor.
Discussion
Modulation of the functions of Ser/Thr phosphatases by means of their interaction with regulatory subunits is 
a recurrent scenario in the biology of the cell. In addition to the ubiquitous eukaryotic PP1c homolog Glc7, the 
budding yeast S. cerevisiae possesses three additional, structurally related PPases, Ppz1, Ppz2 and Ppq1/Sal634. 
Functional studies have revealed a large number (>25) of regulatory subunits of Glc735, whereas only two of them 
(Hal3 and Vhs3) have been identified for Ppz1 (and Ppz2) and, as far as we know, there is no evidence for Ppq1/
Sal6 regulatory subunits. Glc7 provides essential functions to the yeast cell that are not disrupted by the presence 
of other fungus-specific phosphatases, which suggest that, for the most part, Glc7 regulation is separated from 
that of Ppz1. It is worth noting that, in contrast to the existing wealth of information about the mechanisms of 
Figure 6. Hal3 binding capacity and inhibition profile of Ppz1 variants carrying two aminoacid mutations.  
(a) The indicated versions of GST-Ppz1 were immobilized on glutathione beads and processed as described 
in the legend of Fig. 4a. The upper panel reveals the amount of HA-tagged Hal3 bound to the phosphatase. 
The lower panel corresponds to the Ponceau-stained membranes, to show the amount of Ppz1. (b) 
Dephosphorylation assays were carried out as described in Fig. 3. Wild type Ppz1 (-●-); clone 120 (-□-); clone 
121 (-◊-); clone 129 (-Δ-). Values are means ± S.E. for 6 to 10 different assays.
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regulation of mammalian PP1c (and also yeast Glc7), very little is known about how Hal3, the major regulator of 
Ppz1, exerts its function.
The majority (about 2/3) of PP1c (and Glc7) regulators are proteins containing the so-called RVxF motif30, 
which binds to a hydrophobic groove whose structure is strongly conserved in Ppz1 (see Figs 7 and 8). There 
are a number of observations supporting the notion that the RVxF-binding motif is also functionally conserved 
in Ppz1. For instance, in vivo interactions between Ppz1 and two Glc7 regulatory subunits displaying RVxF 
motifs, Glc8 and Ypi1, has been reported by 2-hybrid experiments27. Interaction between Ppz1 and Ypi1 was also 
Figure 7. Alignment of the catalytic domains of Ppz1 from S. cerevisiae (ScPpz1) and C. albicans (CaPpz1), 
with the yeast (ScGlc7) and human (HsPP1c) catalytic subunit of type 1 protein phosphatase. The positions 
of the single mutations described in this work are denoted in yellow background, whereas the three relevant 
mutations found in clones 75, 121 and 129 are in orange. The positions of residues relevant for interaction with 
diverse motifs found in mammalian PP1c regulators (RVxF, SILK, NIPP-1, Arg, Inhibitor-2 helix), which are in 
some cases considerably conserved in Ppz1, or those forming the catalytic site, are indicated at the bottom of the 
sequences using a color code system. Numbering corresponds to the full length proteins. Inh-2, Inhibitor-2.
www.nature.com/scientificreports/
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documented by pull-down assays, and it was demonstrated that a W53A mutation in its 48RHNVRW53 sequence, 
which resembles the characteristic consensus PP1c binding motif, abolished binding to both the Glc7 and Ppz1 
phosphatases29. In addition, both S. cerevisiae and C. albicans Ppz1 are sensitive to mammalian Inhibitor-2, a 
PP1c regulatory subunit that contains a 44RKLHY148 sequence that functionally replaces the RVxF motif36. Hal3 
contains a 263KLHVLF268 sequence that also resembles a RVxF motif. However, it has been shown that mutation 
of H265 or F268 does not affect binding nor inhibitory capacity of Hal3 upon Ppz122, suggesting that this likely 
RVxF motif is not relevant for the interaction with Ppz1. This scenario is in agreement with the fact that we 
did not recover any mutation affecting the hydrophobic groove involved in the binding to RVxF motifs in our 
screen. Therefore, Hal3 must interact with Ppz1 by means of other structural elements different from the RVxF 
motif. Sequence comparisons and recent experimental evidence gathered from studies of the C. albicans Ppz1 
C-terminal domain32 indicate that diverse docking motifs found in PP1c, such as that of either PNUTS or spino-
philin, are not likely to be relevant for yeast Ppz1. The observation that none of the Ppz1 versions tested in this 
work shows significant loss of binding capacity, whereas some of them are clearly refractory to Hal3 inhibition, 
might imply that Ppz1-Hal3 contacts are maintained by multiple interacting elements, still to be defined. In this 
regard, it is worth noting that these interacting determinants should differ from those of type-1 PPases, since it 
has been shown that Hal3 does not bind to Glc7 in vitro13, 29.
As mentioned above, mutations strongly affecting Ppz1-related phenotypes in vivo, as well as the ability to 
be inhibited by Hal3 in vitro, are located at the surface and on the same side of the phosphatase, surrounding 
the access to the catalytic site (Fig. 8). This is interesting because it has been shown that residues 130–169 of 
Figure 8. Mapping mutations and functional elements on a structural model of the C-terminal catalytic moiety 
of ScPpz1. The relevant mutations described in this work are highlighted in yellow and orange (as in Fig. 7). 
Residues involved in the catalytic mechanisms are pink, and the conserved hydrophobic groove, implicated 
in binding to RVxF-containing regulatory subunits, is denoted in green. Residues identical or similar to those 
involved in the interaction of mammalian PP1c with Inhibitor-2 α-helix described in the text are highlighted 
in white. Note that E575, V605, E630, and F631, as well as diverse residues in the catalytic site, although not depicted 
in white, are also involved in PP1c interaction with Inhibitor-2. The correspondence between the annotated 




JA100 MATa ura3-52 leu2-3, 112 his4 trp1-1 can-1r 13
JC010 JA100 slt2::LEU2 47
AGS9 JA100 ppz1::LEU2 48
EDN75 JA100 ppz1:: KANMX4 8
JA104 JA100 hal3::LEU2 13
CCV186 JA100 slt2::LEU2 hal3::KANMX4 16
IM021 JA100 ppz1::KANMX4 hal3::LEU2 22
Table 3. Yeast strains used in this work.
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inhibitor-2, which form the so-called binding site 3, lie along the acidic and hydrophobic substrate binding chan-
nel of PP1c37. This channel is strongly conserved in fungal Ppz1 proteins and includes several residues involved 
in the catalytic mechanism. We observe that most of the phenotypically relevant mutations found in this work, 
affecting Glu575, Val605, Glu630, and Phe631, alter residues which are required for PP1c to interact with inhibitor-2. It 
must be noted that the nature of our screen precludes the isolation of mutations altering catalytic residues (likely 
leading to loss of phosphatase activity). Therefore, it could be hypothesized that the inhibitory strategy of Hal3 
on Ppz1 might mimic that of Inhibitor-2, despite the fact that both proteins exhibit almost no sequence similarity 
(it must be stressed that the overall sequence similarity of Inhibitor-2 and Glc8, its presumed yeast homolog, is 
also very low, <30%). Recently, Choy and coworkers38 postulated that an extended PP1c-interacting motif could 
be identified in diverse regulatory subunits. Such an extended motif would initiate with a more or less degener-
ate RVxF motif and would present the sequence -RVxF-n(5-8)-ΦΦ-n(8-9)-R-, where Φ are hydrophobic residues 
(commonly -VF-). It is remarkable that Hal3 presents a similar sequence -HVLF-n(7)-VF-n(6)KK-, where HVLF is 
the non-functional RVxF-like motif and the Arginine is replaced by another basic residue, Lysine. An equivalent 
sequence, -HVLF-n(7)-VF-n(6)-RK-, is also found in the second Ppz1 inhibitory subunit, Vhs3. In contrast, the 
equivalent sequence in Cab3, a Hal3-related protein that cannot inhibit Ppz1, is -HILI-n(7)-TI-n(6)-DK-, thus 
lacking both the ΦΦ and basic elements. It would be interesting to explore whether or not this structural feature 
has any relevance in Hal3.
In conclusion, the present work provides an initial clue to decipher the mechanism of inhibition of fungal 
Ppz1 by Hal3. It must be noted that Hal3 is a moonlighting protein, acting both as an inhibitor of Ppz1 and as 
a member of an essential heterotrimeric PPCDC enzyme. Accordingly, the core domain of S. cerevisiae Hal3, 
required for efficient interaction with Ppz120, 22, is predicted to display a structured architecture, in contrast with 
most PP1c-interacting proteins, which are intrinsically disordered39. It is likely that the dual function of Hal3 
has determined the evolutionary pace of the protein, thus developing an inhibitory mechanism that may pres-
ent differences from what is currently known for PP1c regulatory subunits. In this regard, it is worth noting the 
important role of the N-terminal segment of Ppz1 (absent in Glc7), consisting of a Ser/Thr rich, basic sequence, 
likely unstructured, which was described long ago to interfere with the binding of Hal3 to the S. cerevisiae Ppz1 
catalytic moiety13 and more recently, in the case of C. albicans Ppz1, to reduce the inhibitory capacity of mam-
malian inhibitor-232. This type of mechanism would help to further insulate Ppz1 and Glc7 functions in yeast.
Methods
Yeast strains and growth conditions. Saccharomyces cerevisiae cells were grown, unless otherwise stated, 
at 28 °C in YPD medium (10 g/L yeast extract, 20 g/L peptone, and 20 g/L dextrose) or in complete minimal 
medium (CM) lacking the appropriate requirements when carrying plasmids for selection40. All yeast strains used 
in this work are listed in Table 3.
Recombinant DNA techniques and plasmids. Escherichia coli DH5α strain was used as plasmid 
DNA host and was grown in LB medium at 37 °C supplemented with 50 μg/ml ampicillin when needed for plas-
mid selection. E.coli strain BL21 (DE3) RIL was used for heterologous protein expression as described below. 
Restriction reactions, DNA ligations, and other standard recombinant DNA techniques, including bacterial and 
yeast transformations were performed using standard methods.
The source for the PPZ1 gene was plasmid YCp33-PPZ1, which contains a 2.7-kbp DNA genomic fragment 
cloned into BamHI/HindIII sites41. Plasmid pRS316-PPZ1 was constructed by digestion of YCp33-PPZ1 with 
BamHI/HindIII and cloning of the 2.7-kbp fragment into the same sites of plasmid pRS31642. The construc-
tion of plasmid YEplac195-PPZ1 was previously described9. The pGEX-6P1 (Amersham Biosciences) plasmid 
was used to express N-terminally GST tagged recombinant proteins in E. coli. Constructs expressing the entire 
S. cerevisiae Ppz1 phosphatase (pGEX6P1-Ppz1) and its C-terminal catalytic domain (lacking residues 1-344) 
(pGEX6P1-Ppz1Cter), as well as pGEX6P1-Hal3, coding for the entire Hal3, have been described previously14.
Random PCR Mutagenesis and screen for Ppz1 deregulated versions. Random PCR mutagen-
esis was performed essentially as in Fromant et al.43 using MgCl2 at a final concentration of 5.5 mM. Plasmid 
pRS316-Ppz1 and oligonucleotides 5′-PPZ1_BsrGI (5′-TGTGCATATGTACATCGTTGAG-3′) and 3′-PPZ1_
BspEI (5′-TAATGCAATCTTCCGGAAAC-3′) were used to amplify the 1.2 kbp fragment between the BsrGI 
and the BspEI sites corresponding to the catalytic domain of Ppz1 (the later located 59 nt downstream the stop 
codon). Four different reactions were made in which the forcing dNTP was at a concentration of 3.4 mM, whereas 
the other dNTPs were at 0.2 mM. The products of various independent PCR reactions were pooled, purified by 
phenol/chloroform/isoamyl alcohol, followed by ethanol precipitation, and digested with BsrGI and BspEI to 
clone in the same sites of the gapped plasmid pRS316-PPZ1. Ligation products were introduced into E. coli com-
petent cells by electroporation44. Approximately 25,000 independent colonies were recovered and mixed.
Strain JC010 (slt2Δ) was transformed with the plasmid library (1 µg DNA/transformation). Approximately 
36,000 transformants were plated in CM-uracil medium containing 4 mM caffeine (around 3,000 transformants/
plate, as determined using control CM plates lacking uracil (CM-uracil)). Plates were incubated for 48–72 h at 
28 °C. Clones able to generate macroscopic colonies under these conditions (usually 10–20/plate) were picked out 
and grown for an additional 3–6 h in sterile 96-well plates filled with CM-uracil medium. They were then spotted 
on CM-uracil plates and in the same plates containing 3 mM, 4 mM or 5 mM caffeine for initial characterization. 
Plasmids from the selected clones were then extracted, amplified in E. coli, and reintroduced into strain JC010 
to reassess the phenotype as indicated above. The catalytic domain of Ppz1 from plasmids providing sustained 
tolerance to caffeine was subjected to sequencing in search of mutations producing a change in the amino acidic 
sequence of the protein.
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Yeast protein extraction and immunoblot analysis. Cells containing plasmids expressing the different 
mutated versions of Ppz1 were tested for integrity and expression levels of the Ppz1 protein. For this purpose, 
S. cerevisiae strain AGS9 (ppz1Δ) was transformed with the different constructs and cells were grown in 10 ml of 
synthetic minimal medium lacking uracil at 28 °C to A660 of 0.8–0.9. Protein extracts were prepared as described 
in20, and forty μg of total protein were resolved by SDS-PAGE. For immunobloting, proteins were transferred 
to Immobilon-P membranes (Millipore), and Ppz1 was immunodetected using anti-GST-Ppz1 polyclonal anti-
bodies (1:250 dilution), followed by anti-rabbit peroxidase secondary antibodies (GE Healthcare) at a 1:20,000 
dilution. The immunocomplexes were visualized using ECL Western blotting detection Kit (GE Healthcare).
Expression of Ppz1 mutated versions in E. coli. The selected mutated versions of PPZ1 were 
expressed in E. coli as follows. The BspEI/BsrGI fragment containing the specific mutations was removed from 
the pRS316-borned construct by digestion with the indicated enzymes, and the resulting 1.2 Kbp fragments 
cloned into the same sites of BspEI/BsrGI gapped pGEX6P1-Ppz1 plasmid. The different versions of Ppz1, 
as well as the Hal3 inhibitor, were expressed E. coli BL21 (DE3) RIL cells as GST-fusion proteins and puri-
fied essentially as previously described14, 19, 29 except that in all cases induction was performed using 0.1 mM 
isopropyl-1-thio-β-D-galactopyranoside, and cultures were grown at 20 °C overnight. Once bound to the 
glutathione-agarose affinity column, when required the recombinant proteins were treated overnight at 4 °C 
with PreScission protease (Amersham Biosciences) following the manufacturer’s indications (80 units/ml resin) 
to cleave the GST moiety. The eluted GST-free proteins were analyzed by SDS-PAGE followed by Coomassie 
Blue-staining (see Supplementary File 5). Due to the presence of lower molecular mass proteins the amount of 
each full-length Ppz1 variant was determined by scanning of the gel using Gel Analyzer software, integration of 
the Ppz1 band and comparison with different amounts of bovine serum albumin.
Assay of protein phosphatase activity. The capacity of Hal3 or Vhs3 as inhibitors of the different 
mutated versions Ppz1 was analyzed using recombinant proteins. To this end, the Ppz1 phosphatase activity was 
measured using p-nitrophenylphosphate as substrate essentially as described previously20, 29 with the following 
modifications: 600 ng of Ppz1 phosphatase was used, the concentration of substrate was 10 mM, and the assay was 
carried out for 20 min at 30 °C. Each phosphatase version was incubated with different amounts of the inhibitor 
for 5 min at 30 °C, and the assay was started immediately by the addition of the substrate.
Detection of protein-protein interactions. The ability of diverse Ppz1versions to bind Hal3 was assessed 
by two different approaches. From one side, in vitro binding assays were performed as follows. Aliquots of the 
glutathione-agarose beads containing 4 μg of GST-Ppz1, GST-Ppz1-Cter, and the diverse GST-Ppz1 mutated 
versions (∼50 μl), were mixed with protein extracts prepared from strain IM021 (ppz1 hal3) transformed with 
the multicopy plasmid pWS93 (negative control) and pWS93-Hal3, carrying a HA-tagged version of Hal3. The 
amounts of extracts used were 0.2 mg for cells expressing S. cerevisiae Hal3, and 2.0 mg for negative controls. 
Binding conditions and analysis were as in20. Samples (15 μl) were analyzed by SDS-PAGE and probed using 
anti-HA antibody (Covance). Membranes were subsequently stained with Ponceau Red to reveal the amount 
of GST-Ppz1 loaded. The relative amounts of Hal3 and Ppz1 were determined by integrating the immunoreac-
tive Hal3 and the Ponceau-stained GST-Ppz1 signals with the Gel Analyzer software and calculating the Hal3/
GST-Ppz1 ratio.
Alternatively, co-expression of Ppz1-Cter carrying selected mutations and Hal3 was carried out in E. coli 
using a polycistronic vector (T7 promoter), in a way that a 6xHis-tagged version of Ppz1-Cter is isolated by 
Ni-affinity chromatography and the co-expressed Hal3 protein is recovered on the basis of its capacity to interact 
with Ppz1-Cter. To this end, N-terminally 6xHis tagged Ppz1-Cter versions and Hal3 were cloned independently 
into pET His TEV LIC cloning vector (2B-T), a gift from Scott Gradia (Addgene plasmid # 29666), to provide the 
required ribosome binding sites, and then both ORFs were transferred to the multicloning site (cassettes 1 and 2) 
of the pET empty polycistronic destination vector (2E) (Addgene plasmid # 29775). Details of the construction 
steps will be published elsewhere. The polycistronic vector generated, named A2-Ppz1-Cter + Hal3, was used 
to transform DH5α competent cells. Positive colonies grown in LB agar plates plus 30 mg/ml Kanamycin were 
recovered and the inserts sequenced to verify the absence of unwanted mutations.
Expression was performed in chemically transformed E.coli BL21 (DE3) RIL cells grown in LB supplemented 
with 30 µg/ml kanamycin and 34 µg/ml chloramphenicol by an auto-induction method. For this, a preculture 
of 10 ml of LB supplemented with 1% glucose and the selection antibiotics was grown at 37 °C for 16–18 h at 
230 rpm. This culture was used to inoculate 50 ml of auto-induction media (to be described elsewhere) supple-
mented with 100 µg/ml kanamycin to an OD600 of at least 0.05, and the culture was growth at 230 rpm and 37 °C 
to reach a density of OD600 = 0.6–1.2. At this point, temperature was decreased to 20 °C and growth continued for 
about 48 h. Cells were then collected by centrifugation at 6,500 xg for 20 min at 4 °C and pellets were resuspend in 
8 ml of binding buffer (50 mM Tris-HCl pH 8, 100 mM NaCl, 10 mM imidazole) supplemented with 0.1% Triton 
X-100, 1 mM DTT, 1 mM PMSF and protease inhibitor cocktail (complete EDTA-free, Roche). The suspension 
was sonicated and then centrifuged at 4 °C (12,000 xg for 30 minutes) to remove cellular debris. The 6x-His tagged 
Ppz1-Cter protein was purified from the cell extract by gravity-flow chromatography using an Ni-NTA agarose 
matrix (Quiagen). After loading the lysate, the matrix was washed with binding buffer supplemented with 50 mM 
imidazole, and the protein complex subsequently eluted after incubation for one h with the same buffer contain-
ing 500 mM imidazole. Samples (15 μl) were analyzed by SDS-PAGE and stained with Coomassie Blue or BlueSafe 
(#MB15201, NzyTech).
Phenotypic analysis of yeast cells. Tolerance to caffeine or LiCl of S. cerevisiae cells carrying the plasmids 
with the different Ppz1 mutated versions was evaluated by growth on plates (drop tests) as described previously2. 
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Tolerance in liquid cultures was tested by monitoring growth rate of a starting culture (OD600 nm of 0.05) for 24 h 
in a Bioscreen C equipment (Labsystems). Measures were taken every 30 min. The calculation of the time needed 
to reach a given OD was calculated by solving the exponential equation fitted to the growth curve. Flocculation 
assays were performed as in45 except that after the addition of calcium chloride (that induces flocculation), tubes 
were shaken at 28 °C (230 strokes/min) for 5 min and left standing for 5 min. A sample of the supernatant was 
then taken, made 0.25 M EDTA, and the OD600 measured. The flocculation index is calculated as the ratio of the 
OD600 between the fully deflocculated cell suspension and the EDTA-treated supernatant.
For modelling studies the sequence comprising residues 361 to 692 of S. cerevisiae Ppz1 was submitted to the 
Swiss-Model Web Sever46. Models were built based on the target-template alignment using ProMod3 and the 
3D-structure of C. albicans C-terminal Ppz1 protein (5jpe)32.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files). Protocols, DNA constructs, and other materials generated in this work will 
be made available without restrictions upon request to the corresponding author.
References
 1. Posas, F., Casamayor, A., Morral, N. & Arino, J. Molecular cloning and analysis of a yeast protein phosphatase with an unusual 
amino-terminal region. J. Biol. Chem. 267, 11734–11740 (1992).
 2. Posas, F., Camps, M. & Ariño, J. The PPZ protein phosphatases are important determinants of salt tolerance in yeast cells. J. Biol. 
Chem. 270, 13036–13041 (1995).
 3. Ruiz, A., Yenush, L. & Arino, J. Regulation of ENA1 Na(+)-ATPase gene expression by the Ppz1 protein phosphatase is mediated by 
the calcineurin pathway. Eukaryot. Cell 2, 937–948 (2003).
 4. Yenush, L., Mulet, J. M., Ariño, J. & Serrano, R. The Ppz protein phosphatases are key regulators of K+ and pH homeostasis: 
implications for salt tolerance, cell wall integrity and cell cycle progression. EMBO J 21, 920–929 (2002).
 5. Yenush, L., Merchan, S., Holmes, J. & Serrano, R. pH-Responsive, Posttranslational Regulation of the Trk1 Potassium Transporter 
by the Type 1-Related Ppz1 Phosphatase. Mol Cell Biol 25, 8683–8692 (2005).
 6. Posas, F., Casamayor, A. & Ariño, J. The PPZ protein phosphatases are involved in the maintenance of osmotic stability of yeast cells. 
FEBS Lett. 318, 282–286 (1993).
 7. Lee, K. S., Hines, L. K. & Levin, D. E. A pair of functionally redundant yeast genes (PPZ1 and PPZ2) encoding type 1-related protein 
phosphatases function within the PKC1-mediated pathway. Mol. Cell Biol. 13, 5843–5853 (1993).
 8. De Nadal, E. et al. A role for the Ppz Ser/Thr protein phosphatases in the regulation of translation elongation factor 1Balpha. J. Biol.
Chem. 276, 14829–14834 (2001).
 9. Clotet, J., Garí, E., Aldea, M. & Ariño, J. The yeast ser/thr phosphatases sit4 and ppz1 play opposite roles in regulation of the cell 
cycle. Mol. Cell Biol. 19, 2408–2415 (1999).
 10. Makanae, K., Kintaka, R., Makino, T., Kitano, H. & Moriya, H. Identification of dosage-sensitive genes in Saccharomyces cerevisiae 
using the genetic tug-of-war method. Genome. Res. 23, 300–311 (2013).
 11. Di Como, C. J., Bose, R. & Arndt, K. T. Overexpression of SIS2, which contains an extremely acidic region, increases the expression 
of SWI4, CLN1 and CLN2 in sit4 mutants. Genetics 139, 95–107 (1995).
 12. Ferrando, A., Kron, S. J., Rios, G., Fink, G. R. & Serrano, R. Regulation of cation transport in Saccharomyces cerevisiae by the salt 
tolerance gene HAL3. Mol. Cell Biol. 15, 5470–5481 (1995).
 13. De Nadal, E. et al. The yeast halotolerance determinant Hal3p is an inhibitory subunit of the Ppz1p Ser/Thr protein phosphatase. 
Proc. Natl. Acad. Sci. USA 95, 7357–7362 (1998).
 14. Ruiz, A. et al. Functional characterization of the Saccharomyces cerevisiae VHS3 gene: a regulatory subunit of the Ppz1 protein 
phosphatase with novel, phosphatase-unrelated functions. J. Biol. Chem. 279, 34421–34430 (2004).
 15. Ádám, C. et al. Protein phosphatase CaPpz1 is involved in cation homeostasis, cell wall integrity and virulence of Candida albicans. 
Microbiology 158, 1258–1267 (2012).
 16. Petrényi, K. et al. Analysis of Two Putative Candida albicans Phosphopantothenoylcysteine Decarboxylase/Protein Phosphatase Z 
Regulatory Subunits Reveals an Unexpected Distribution of Functional Roles. PLoS One 11, e0160965 (2016).
 17. Molero, C. et al. The Schizosaccharomyces pombe fusion gene hal3 encodes three distinct activities. Mol. Microbiol. 90, 367–382 
(2013).
 18. Minhas, A. et al. A conserved Ser/Arg rich motif in PPZ orthologs from fungi is important for its role in cation tolerance. J. Biol. 
Chem. (2012).
 19. Ruiz, A. et al. Moonlighting proteins Hal3 and Vhs3 form a heteromeric PPCDC with Ykl088w in yeast CoA biosynthesis. Nat.
Chem.Biol. 5, 920–928 (2009).
 20. Abrie, J. A. A., González, A., Strauss, E. & Ariño, J. Functional mapping of the disparate activities of the yeast moonlighting protein 
Hal3. Biochem. J. 442, 357–68 (2012).
 21. Abrie, J. A., Molero, C., Ariño, J. & Strauss, E. Complex stability and dynamic subunit interchange modulates the disparate activities 
of the yeast moonlighting proteins Hal3 and Vhs3. Sci. Rep. 5 (2015).
 22. Munoz, I. et al. Functional characterization of the yeast Ppz1 phosphatase inhibitory subunit Hal3: a mutagenesis study. J. Biol. 
Chem. 279, 42619–42627 (2004).
 23. Kovacs, L. et al. The polymorphism of protein phosphatase Z1 gene in Candida albicans. J. Basic Microbiol. 50(Suppl 1), S74–S82 
(2010).
 24. Leiter, É. et al. Protein phosphatase Z modulates oxidative stress response in fungi. Fungal Genet. Biol. 49, 708–716 (2012).
 25. Clotet, J. et al. The gene DIS2S1 is essential in Saccharomyces cerevisiae and is involved in glycogen phosphorylase activation. Curr.
Genet. 19, 339–342 (1991).
 26. Feng, Z. H. et al. The yeast GLC7 gene required for glycogen accumulation encodes a type 1 protein phosphatase. J. Biol. Chem. 266, 
23796–23801 (1991).
 27. Venturi, G. M., Bloecher, A., Williams-Hart, T. & Tatchell, K. Genetic interactions between GLC7, PPZ1 and PPZ2 in saccharomyces 
cerevisiae. Genetics 155, 69–83 (2000).
 28. Posas, F., Bollen, M., Stalmans, W. & Ariño, J. Biochemical characterization of recombinant yeast PPZ1, a protein phosphatase 
involved in salt tolerance. FEBS Lett. 368, 39–44 (1995).
 29. Garcia-Gimeno, M. A., Munoz, I., Arino, J. & Sanz, P. Molecular characterization of Ypi1, a novel Saccharomyces cerevisiae type 1 
protein phosphatase inhibitor. J.Biol.Chem. 278, 47744–47752 (2003).
 30. Bollen, M., Peti, W., Ragusa, M. J. & Beullens, M. The extended PP1 toolkit: designed to create specificity. Trends Biochem. 35, 
450–458 (2010).
 31. González, A., Casado, C., Petrezsélyová, S., Ruiz, A. & Ariño, J. Molecular analysis of a conditional hal3 vhs3 yeast mutant links 
potassium homeostasis with flocculation and invasiveness. Fungal Genet. Biol. 53, 1–9 (2013).
www.nature.com/scientificreports/
1 4ScIentIfIc RepoRts | 7: 8819  | DOI:10.1038/s41598-017-09360-5
 32. Chen, E. et al. Molecular Insights into the Fungus-Specific Serine/Threonine Protein Phosphatase Z1 in Candida albicans. MBio 7, 
e00872–16 (2016).
 33. Hurley, T. D. et al. Structural basis for regulation of protein phosphatase 1 by inhibitor-2. J. Biol. Chem. 282, 28874–83 (2007).
 34. Arino, J. Novel protein phosphatases in yeast. Eur. J. Biochem. 269, 1072–1077 (2002).
 35. Cannon, J. F. Function of protein phosphatase-1, Glc7, in Saccharomyces cerevisiae. Adv. Appl. Microbiol. 73, 27–59 (2010).
 36. Wakula, P., Beullens, M., Ceulemans, H., Stalmans, W. & Bollen, M. Degeneracy and function of the ubiquitous RVXF motif that 
mediates binding to protein phosphatase-1. J. Biol. Chem. 278, 18817–18823 (2003).
 37. Hurley, R. L. et al. The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 
280, 29060–29066 (2005).
 38. Choy, M. S. et al. Understanding the antagonism of retinoblastoma protein dephosphorylation by PNUTS provides insights into the 
PP1 regulatory code. Proc. Natl. Acad. Sci. USA 111, 4097–102 (2014).
 39. Heroes, E. et al. The PP1 binding code: a molecular-lego strategy that governs specificity. FEBS J. 280, 584–595 (2013).
 40. Adams, A., Gottschling, D. E., Kaiser, C. A. & Stearns, T. Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual. 
(Cold Spring Harbor Laboratory Press, 1998).
 41. Aksenova, A., Muñoz, I., Volkov, K., Ariño, J. & Mironova, L. The HAL3-PPZ1 dependent regulation of nonsense suppression 
efficiency in yeast and its influence on manifestation of the yeast prion-like determinant [ISP+]. Genes to Cells 12, 435–445 (2007).
 42. Sikorski, R. S. & Hieter, P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in 
Saccharomyces cerevisiae. Genetics 122, 19–27 (1989).
 43. Fromant, M., Blanquet, S. & Plateau, P. Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. 
Anal. Biochem. 224, 347–353 (1995).
 44. Inoue, H., Nojima, H. & Okayama, H. High efficiency transformation of Escherichia coli with plasmids. Gene 96, 23–8 (1990).
 45. Bony, M., Barre, P. & Blondin, B. Distribution of the flocculation protein, flop, at the cell surface during yeast growth: the availability 
of flop determines the flocculation level. Yeast 14, 25–35 (1998).
 46. Bordoli, L. et al. Protein structure homology modeling using SWISS-MODEL workspace. Nat. Protoc. 4, 1–13 (2009).
 47. Vissi, E. et al. Functional analysis of the Neurospora crassa PZL-1 protein phosphatase by expression in budding and fission yeast. 
Yeast 18, 115–124 (2001).
 48. Canadell, D., González, A., Casado, C. & Ariño, J. Functional interactions between potassium and phosphate homeostasis in 
Saccharomyces cerevisiae. Mol. Microbiol. 95, 555–572 (2015).
Acknowledgements
Thanks are given to Montserrat Robledo for technical support, to Dr. L. Tabernero and E. Ceh-Pavia (University 
of Manchester) for help and advice in E. coli co-expression experiments, and to Dr. L. Yenush (Universidad 
Politécnica de Valencia) for critical reading of the manuscript. The support of the members of the Servei de 
Genòmica i Bionformàtica (UAB) is acknowledged. This work was supported by grants BFU2011-30197-C3-01 
and BFU2014-54591-C2-1-P (Ministerio de Industria, Economía y Competitividad, Spain) and an “Ajut 
2014SGR-4” (Generalitat de Catalunya) to JA. CM was recipient of a FPI fellowship (BES-2012-058498) from the 
Ministerio de Industria, Economía y Competitividad, Spain.
Author Contributions
C.M. performed most of the experiments. C.C. established the conditions for the functional screen and 
constructed the library of mutants. J.A. designed and supervised the project, and wrote the paper. All authors 
reviewed the manuscript.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-09360-5
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
